SC 13G/A: Theravance Biopharma, Inc.
Ticker: TBPH · Form: SC 13G/A · Filed: Jun 11, 2024 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | SC 13G/A |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Theravance Biopharma, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Theravance Biopharma, Inc. (ticker: TBPH) to the SEC on Jun 11, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
How long is this filing?
Theravance Biopharma, Inc.'s SC 13G/A filing is 3 pages with approximately 995 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 995 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2024-06-11 16:17:37
Filing Documents
- g610240sc13ga1.htm (SC 13G/A) — 43KB
- 0001214659-24-010814.txt ( ) — 45KB
(a)
Item 1(a). Name of Issuer : Theravance Biopharma, Inc.
(b)
Item 1(b). Address of Issuer’s Principal Executive Offices : 901 Gateway Boulevard South San Francisco, CA 94080
(a)
Item 2(a). Name of Person Filing : This Schedule 13G is filed jointly by: (1) ODRE 2005 SL (2) Luis Gómez Laguna The agreement between the reporting persons relating to the joint filing of this Schedule 13G is attached hereto as Exhibit 1 .
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence : Pineta, 18B, Polígono Valdeconsejo, Nave 5, CP50410, Cuarte de Huerva (Zaragoza), Spain
(c)
Item 2(c). Citizenship : ODRE 2005 SL is sociedad limitada organized under the laws of Spain. Mr. Gómez Laguna is a citizen of Spain.
(d)
Item 2(d). Title of Class of Securities : Ordinary Shares
(e)
Item 2(e). CUSIP Number : G8807B106 Item 3. Not applicable Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 0 (b) Percent of Class: 0.0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x . Item 6. No. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibits: 1 Joint Filing Agreement, dated as of June 11, 2024, by and between ODRE 2005 SL and Luis Gómez Laguna SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in